Site Map
- About Us
- Our Products
- Product Sites
- Patient Safety
- News and Media
- Fact Sheets
- Press Releases
- American Nurses Foundation Announces New Scholarship Fund Supported by Grant from Fresenius Kabi
- Fresenius Kabi USA Launches Treatment for Acetaminophen Overdose
- Fresenius Kabi Announces Availability of Acetylcysteine Solution, USP
- Fresenius Kabi Announces Launch of Oxaliplatin Injection, USP Latest APP Oncology Product Now Available
- APP Pharmaceuticals Acquires Three Products From Nexus. Benztropine Mesylate, Levetiracetam and Tranexamic Acid Injectables are Newest Additions to Critical Care Portfolio.
- APP Pharmaceuticals Announces Approval of Preservative-Free Methotrexate Injection, USP
- APP Pharmaceuticals Announces Launch of Imipenem and Clilastatin for Injection, USP and Meropenen for Injection, USP
- APP Pharmaceuticals Settles with the Medicines Company on Angiomax® (Bivalirudin) Patent Litigation
- APP Pharmaceuticals Announces Increased Availability of APP Diprivan® and APP Propofol 1%
- APP Pharmaceuticals Announces Approval and Launch of Clonidine Hydrochloride Injection
- APP Pharmaceuticals Announces Approval of Nafcillin For Injection, USP
- APP Pharmaceuticals Announces Approval Of Levothyroxine Sodium For Injection
- APP Pharmaceuticals Invests $38 Million to Expand Its Grand Island, New York Manufacturing Facility
- APP Pharmaceuticals Named NOVAPLUS® Pharmacy Manufacturer of the Year
- APP Pharmaceuticals to Market Letrozole Tablets, USP in the U.S.
- APP Pharmaceuticals Receives Approval for Piperacillin and Tazobactam for Injection
- APP Pharmaceuticals Announces Approval and Launch of Gemcitabine HCI for Injection, USP in 2 Gram Dosage Form
- Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist and Deregister Contingent Value Rights for APP Pharmaceuticals
- Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals, Inc. (APP)
- APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
- APP Pharmaceuticals Announces Approval and Launch of Topotecan for Injection
- APP Pharmaceuticals to Launch Drug Hotline
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- APP Pharmaceuticals Announces Approval of Metoprolol Tartrate Injection, USP
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- APP Pharmaceuticals Announces Marketing Clearance of Preservative-Free Heparin Lock Flush Solution, USP
- APP Pharmaceuticals to Market Anastrozole Tablets in the U.S.
- APP Pharmaceuticals Announces Approval of Ganciclovir for Injection, USP
- APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
- APP Pharmaceuticals to Market Oxaliplatin Injection (Liquid) in the U.S.
- APP Pharmaceuticals Receives Approval for Lyophilized Oxaliplatin for Injection
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- Fresenius Kabi Enters Into Licensing and Settlement Agreements with sanofi-aventis
- APP Pharmaceuticals Receives Approval for Indomethacin for Injection
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-K
- Thomas H. Silberg to Retire as President and CEO of APP Pharmaceuticals, John Ducker Named as Successor
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- Bernhard Hampl, Ph.D. Elected to Serve as Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.
- APP Pharmaceuticals Receives Approval for the First Generic Chlorothiazide Sodium for Injection, USP
- APP Pharmaceuticals Receives Approval for Sumatriptan Succinate Injection, USP
- APP Pharmaceutical Supports New USP Standards for Unfractionated Heparin
- APP Pharmaceuticals Receives Approval for Deferoxamine Mesylate for Injection, USP
- APP Pharmaceuticals Receives Approval for Penicillin G Potassium for Injection, USP
- APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q
- FRESENIUS KABI PHARMACEUTICALS HOLDING, INC,ANNOUNCES FILING OF FORM 10-K
- APP Pharmaceuticals Launches Rocuronium Bromide Injection
- APP Pharmaceuticals Launches Heparin-Focused Educational Web Site Called “Working Together For Patient Safety”
- Fresenius Kabi Pharmaceuticals Holding, Inc. Releases Third Quarter Results
- Fresenius SE Parent Company of Fresenius Kabi Pharmaceuticals Holding, Inc., Announces Date for Third Quarter Earnings
- APP Pharmaceuticals Announces Completion of Acquisition by Fresenius
- APP Pharmaceuticals Announces Trading Information on NASDAQ of Contingent Value Rights Associated with the Acquisition by Fresenius
- APP Pharmaceuticals and Fresenius Announce Clearance of APP Acquisition by U.S. Federal Trade Commission
- APP Pharmaceuticals Receives Manufacturing Approval for Three Product Codes of Heparin at Puerto Rico Facility
- APP Pharmaceuticals Reports 2008 Second Quarter Net Revenues of $198 Million, Operating Income of $53 Million
- APP Pharmaceuticals Announces Date for 2008 Second Quarter Financial Results and Investor Conference Call
- APP Pharmaceuticals to Be Acquired by Fresenius
- APP Pharmaceuticals Receives Final Approvals for Additional Dosages of Granisetron Hydrochloride Injection, USP
- APP Pharmaceuticals Launches Enhanced Labeling for Heparin Sodium Injection, USP
- APP Pharmaceuticals Provides Update on Issues Related to Heparin Crisis and Actions to Ensure Uninterrupted Safe Supply
- APP Pharmaceuticals Reports 2008 First Quarter Net Revenues of $148 Million, Gross Profit of $70 Million
- APP Pharmaceuticals Announces Date for 2008 First Quarter Financial Results and Investor Conference Call
- APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer
- APP Pharmaceuticals Receives FDA Approval for Colistimethate For Injection, USP
- APP Pharmaceuticals Launches Cefepime Hydrochloride for Injection
- APP Pharmaceuticals Reports Record Net Revenues of $647 Million and Gross Profit of $315 Million from Continuing Operations in 2007
- APP Pharmaceuticals Announces Date for Fourth Quarter and Full-Year Financial Results and Investor Conference Call
- APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
- APP Pharmaceuticals Announces Plan to Respond to Potential Therapeutic Heparin Shortage in the United States
- APP Pharmaceuticals Receives FDA Approval for Caffeine Citrate Oral Solution, USP
- APP Pharmaceuticals Receives FDA Approval for Bleomycin Sulfate for Injection, USP
- APP Pharmaceuticals Launches Granisetron Hydrochloride Injection, USP
- APP Pharmaceuticals Receives FDA Approval for Polymyxin B Sulfate for Injection, USP
- Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
- APP Receives FDA Approval for Epirubicin HCl Injection
- APP Receives Two FDA Approvals for Fludarabine Phosphate
- Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
- APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials
- APP Receives Tentative Approval for Granisetron Hydrochloride Injection, USP
- Abraxis BioScience to Present at the Bear Stearns Healthcare Conference
- Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer
- APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
- Abraxis BioScience Reports Second Quarter 2007 Revenue of $243 Million versus $161 Million in Prior Year Period
- Abraxis BioScience Announces Licensing Agreement with Biocon Limited for the Commercialization of ABRAXANE in India
- Abraxis BioScience Launches Doxorubicin Hydrochloride Injection, USP
- Abraxis BioScience Receives FDA Approval for Oxytocin Injection 10 USP Units/mL in a 30 mL Vial
- Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
- Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL
- Abraxis BioScience Acquires Manufacturing Facility from Watson
- Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development of New Nanobiotechnologies
- Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
- Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call
- Abraxis BioScience Announces Plan to Separate Into Two Independent Public Companies
- Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer from the University of Southern California
- Abraxis BioScience to Present at the Goldman Sachs 28th Annual Global Healthcare Conference
- ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
- New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
- Abraxis BioScience to Present at the Bank of America 2007 Health Care Conference
- Abraxis BioScience Founder Awarded Ellis Island Medal of Honor
- Abraxis BioScience Reports First Quarter 2007 Revenue of $212.2 Million Versus $144.5 Million in Prior Year Period
- Abraxis BioScience Announces Joint Venture With Cenomed for the Development of Novel Therapeutics for Neurological Diseases
- Abraxis BioScience Receives FDA Tentative Approval for Fosphenytoin Sodium Injection, USP
- Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (ABRAXANE(R)) with Anti-Angiogenic Agents to Increase Tumor Response
- Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin's Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
- Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab(TM)) Technology Platform in Targeting the Pathway
- Abraxis BioScience Announces Date for First Quarter Financial Results and Investor Conference Call
- Abraxis BioScience to Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
- Abraxis BioScience to Initiate Two Phase I/II Clinical Trials with nab-docetaxel in Hormone Refractory Prostate and Metastatic Breast Cancer
- Abraxis BioScience Reports Record Revenue of $765 Million in 2006 Versus $521 Million for 2005
- Abraxis Bioscience Completes Acquisition of Manufacturing Complex from Pfizer
- Abraxis BioScience Announces Date for Fourth Quarter and Full Year Financial Results and Investor Conference Call
- Abraxis BioScience to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
- Abraxis BioScience to Present at the Wachovia Small and Mid-Cap Healthcare Conference
- Abraxis BioScience Files Marketing Application for ABRAXANE in Australia
- Abraxis BioScience to Present at the JPMorgan Healthcare Conference
- Abraxis BioScience Launches Ondansetron Injection, USP
- Contact
- RSS Feeds
- Careers
Print this page